| Bioactivity | Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats[1]. | ||||||||||||
| In Vivo | Zenarestat (3.2, 32 mg/kg; p.o.; daily for 8 weeks) inhibits nerve sorbitol accumulation in a dose-dependent manner[1]. Animal Model: | ||||||||||||
| Name | Zenarestat | ||||||||||||
| CAS | 112733-06-9 | ||||||||||||
| Formula | C17H11BrClFN2O4 | ||||||||||||
| Molar Mass | 441.64 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Shimoshige Y, et al. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats. Metabolism. 2000;49(11):1395-1399. |
Zenarestat
CAS: 112733-06-9 F: C17H11BrClFN2O4 W: 441.64
Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.